Structure, Function and Drug Targets of The Asb2-Elongin BC-Cul5-Rbx2 Complex

Target Name: Ubiquitin E3 ligase (ASB2, TCEB1, TCEB2, CUL5, RNF7) complex

NCBI ID: P25396

Ubiquitin E3 ligase (ASB2, TCEB1, TCEB2, CUL5, RNF7) complex

Other Name(s): Asb2-Elongin BC-Cul5-Rbx2 complex | SCF-like ECS E3 ubiquitin ligase complex | Ubiquitin E3 ligase (ASB2, TCEB1, TCEB2, CUL5, RNF7) | SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex

Structure, Function and Drug Targets of The Asb2-Elongin BC-Cul5-Rbx2 Complex

Ubiquitin E3 ligase (ASB2, TCEB1, TCEB2, CUL5, RNF7) complex, also known as the Asb2-Elongin BC-Cul5-Rbx2 complex, is a protein complex that plays a crucial role in the regulation of protein degradation in eukaryotic cells. The complex is composed of five proteins: ASB2, TCEB1, TCEB2, CUL5, and RNF7. In this article, we will discuss the structure, function, and potential drug targets of this complex.

Structure
The Asb2-Elongin BC-Cul5-Rbx2 complex is a monomeric protein complex that consists of a core region of the protein Asb2, which contains a nucleotide-binding oligomerization domain (NBD), a nucleotide-binding oligomerization domain (NBD), a carboxy -terminal domain (CTD), a N-terminal domain (NTD), and a C-terminal domain (CTD). The NBDs and NTDs in Asb2 interact with each other to form a N-end rule, while the C-terminal domain interacts with the N-terminal domain of the protein TCEB1. The TCEB1 protein contains a nucleotide-binding oligomerization domain (NBD), a nucleotide-binding oligomerization domain (NBD), a carboxy-terminal domain (CTD), and a C-terminal domain (CTD). The CUL5 protein contains a nucleotide-binding oligomerization domain (NBD), a nucleotide-binding oligomerization domain (NBD), a carboxy-terminal domain (CTD), and a C-terminal domain (CTD). The RNF7 The protein contains a nucleotide-binding oligomerization domain (NBD), a nucleotide-binding oligomerization domain (NBD), a carboxy-terminal domain (CTD), and a C-terminal domain (CTD).

Function
The Asb2-Elongin BC-Cul5-Rbx2 complex plays a crucial role in the regulation of protein degradation in eukaryotic cells. It is involved in the formation of the N-end rule, which is a critical step in the degradation pathway of many proteins. The N-end rule is a consensus sequence that is present at the end of a transmembrane protein or a cytoplasmic protein. It is composed of a specific nucleotide sequence that is recognized by the ubiquitin E3 ligase. The Asb2 protein in the Asb2-Elongin BC -Cul5-Rbx2 complex interacts with the N-end rule and forms the N-end rule complex. This complex is responsible for the N-end rule formation and for the efficient degradation of many proteins.

Drug Targets
The Asb2-Elongin BC-Cul5-Rbx2 complex is a potential drug target for several diseases. One of the main goals of drug development is to identify compounds that can inhibit the activity of this complex and prevent protein degradation. This can be done by targeting specific proteins in the complex or targeting by the complex as a whole. There are several known drugs that have been shown to inhibit the activity of the Asb2-Elongin BC-Cul5-Rbx2 complex, including:

1. Ubiquitinconjugated ubiquitin: Ubiquitinconjugated ubiquitin is a naturally occurring compound in living organisms that has the effects of inhibiting ubiquitinase activity, anti-tumor and anti-inflammatory effects. Can be used as a drug to inhibit AS

Protein Name: Ubiquitin E3 Ligase (ASB2, TCEB1, TCEB2, CUL5, RNF7) Complex

The "Ubiquitin E3 ligase (ASB2, TCEB1, TCEB2, CUL5, RNF7) complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Ubiquitin E3 ligase (ASB2, TCEB1, TCEB2, CUL5, RNF7) complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets